Fidelity Investments
DNTH icon

Fidelity Investments’s Dianthus Therapeutics DNTH Stock Holding History

Fidelity Investments’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$799M Buy
8,199,893
+432,207
+6% +$37.7M 0.03% 394
2026
Q1 		$652M Buy
7,767,686
+1,336,357
+21% +$77.4M 0.03% 420
2025
Q4 		$265M Buy
6,431,329
+460,691
+8% +$17.9M 0.01% 749
2025
Q3 		$235M Buy
5,970,638
+1,426,450
+31% +$36.5M 0.01% 775
2025
Q2 		$84.7M Buy
4,544,188
+61,579
+1% +$1.16M ﹤0.01% 1187
2025
Q1 		$81.3M Buy
4,482,609
+43,328
+1% +$955K 0.01% 1175
2024
Q4 		$96.8M Buy
4,439,281
+36,133
+0.8% +$929K 0.01% 1135
2024
Q3 		$121M Buy
4,403,148
+728
+0% +$20.3K 0.01% 1022
2024
Q2 		$114M Buy
4,402,420
+241,375
+6% +$5.8M 0.01% 1000
2024
Q1 		$125M Buy
4,161,045
+1,942,833
+88% +$42.2M 0.01% 972
2023
Q4 		$22.6M Hold
2,218,212
– – ﹤0.01% 1581
2023
Q3 		$29M Buy
+2,218,212
New +$27.9M ﹤0.01% 1456
2023
Q2 		– Sell
-16
Closed -$202 – 5418
2023
Q1 		$202 Buy
+16
New +$177 ﹤0.01% 4852
2022
Q4 		– Sell
-36
Closed -$1K – 5395
2022
Q3 		$1K Sell
36
-12
-25% -$329 ﹤0.01% 4646
2022
Q2 		$1K Buy
48
+16
+50% +$395 ﹤0.01% 4692
2022
Q1 		$1K Sell
32
-46,537
-100% -$2.54M ﹤0.01% 4776
2021
Q4 		$3.3M Hold
46,569
– – ﹤0.01% 2458
2021
Q3 		$5.42M Hold
46,569
– – ﹤0.01% 2340
2021
Q2 		$7.29M Buy
46,569
+4,550
+11% +$836K ﹤0.01% 2219
2021
Q1 		$7.96M Buy
42,019
+35,931
+590% +$6.05M ﹤0.01% 2121
2020
Q4 		$764K Hold
6,088
– – ﹤0.01% 2574
2020
Q3 		$662K Hold
6,088
– – ﹤0.01% 2484
2020
Q2 		$731K Sell
6,088
-2,544
-29% -$358K ﹤0.01% 2450
2020
Q1 		$867K Hold
8,632
– – ﹤0.01% 2350
2019
Q4 		$2.09M Hold
8,632
– – ﹤0.01% 2242
2019
Q3 		$1.42M Buy
8,632
+988
+13% +$188K ﹤0.01% 2360
2019
Q2 		$1.8M Buy
+7,644
New +$1.89M ﹤0.01% 2352

Other funds holding DNTH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments's DNTH Position: Q2 2026 in Review

Fidelity Investments increased its Dianthus Therapeutics (DNTH) stake by 5.6% in Q2 2026, buying an estimated $37.7M and bringing the position to 8,199,893 shares worth $799M. The position accounts for 0.03% of the portfolio, ranked #394.

Fidelity Investments first reported a position in DNTH in Q2 2019 and has held it in 27 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Fidelity Investments held 8,199,893 shares of Dianthus Therapeutics worth $799M as of Q2 2026.
  • Fidelity Investments bought 432,207 Dianthus Therapeutics shares in Q2 2026, an estimated $37.7M.
  • Dianthus Therapeutics made up 0.03% of Fidelity Investments's portfolio in Q2 2026, its #394 holding.
  • Fidelity Investments first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.